Diversity of moxifloxacin resistance during a nosocomial outbreak of a predominantly ribotype ARU 027 Clostridium difficile diarrhea

Anaerobe

Volumn 15, Issue 6, 2009, Pages 244-248

  Carman, Robert J ^a   Genheimer, Christopher W ^a   Rafii, Fatemeh ^b   Park, Miseon ^b   Hiltonsmith, Megan F ^a   Lyerly, David M ^a  

^a TECHLAB INC   (United States)

^b NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH   (United States)

Author keywords

Clostridium difficile; gyrA; gyrB; MAMA; Moxifloxacin; PCR; QRDR; Quinolone; Resistance; SNP

Indexed keywords

ALANINE; ARGININE; ASPARAGINE; ASPARTIC ACID; CLOSTRIDIUM DIFFICILE TOXIN A; CLOSTRIDIUM DIFFICILE TOXIN B; DNA TOPOISOMERASE (ATP HYDROLYSING) A; GLUTAMATE DEHYDROGENASE; GLUTAMIC ACID; ISOLEUCINE; LYSINE; MOXIFLOXACIN; SERINE; THREONINE; VALINE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GENE; BACTERIAL STRAIN; BACTERIUM ISOLATE; BACTERIUM MUTANT; CLOSTRIDIUM DIFFICILE; CONTROLLED STUDY; EPIDEMIC; GENE MUTATION; GENETIC ASSOCIATION; HOSPITAL INFECTION; HUMAN; INFECTIOUS DIARRHEA; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; RIBOTYPING; WILD TYPE;

ANTI-BACTERIAL AGENTS; AZA COMPOUNDS; CLOSTRIDIUM DIFFICILE; CROSS INFECTION; DIARRHEA; DISEASE OUTBREAKS; DNA GYRASE; DRUG RESISTANCE, BACTERIAL; ENTEROCOLITIS, PSEUDOMEMBRANOUS; GENETIC VARIATION; HUMANS; MICROBIAL SENSITIVITY TESTS; MUTATION; POLYMERASE CHAIN REACTION; QUINOLINES; RIBOTYPING;

CLOSTRIDIUM DIFFICILE;

EID: 70450267459     PISSN: 10759964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.anaerobe.2009.09.009     Document Type: Article

References (28)

1. Stubss S.L.J., Brazier J.S., O'Neill G.L., and Duerden B.I. PCR targeted to the 16S-23S rRNA gene intergenic spacer region of Clostridium difficile and construction of a library consisting of 116 different PCR ribotypes. J Clin Microbiol 37 (1999) 461-463
2. MacDonald L.C., Killgore G.E., Thompson A., Owens Jr. R.C., Kazakova S.V., Sambol S.P., et al. An epidemic, toxin gene-variant strain of Clostridium difficile. New Engl J Med 353 (2005) 2433-2441
3. McEllistrem M.C., Carman R.J., Gerding D.N., Genheimer C.W., and Zheng L. A hospital outbreak of Clostridium difficile disease associated with isolates carrying binary toxin genes. Clin Infect Dis 40 (2005) 265-272
4. Rupnik M., Dupuy B., Fairweather N.F., Gerding D.N., Johnson S., Just I., et al. Revised nomenclature of Clostridium difficile toxins and associated genes. J Med Microbiol 54 (2005) 113-117
5. Drudy D., Quinn T., O'Mahony R., Kyne L., O'Gaora P., and Fanning S. High-level resistance to moxifloxacin and gatifloxacin associated with a novel mutation in gyrB in toxin-A-negative, toxin-B-positive Clostridium difficile. J Antimicrob Chemother 46 (2006) 3418-3421
6. Drudy D., Harnedy N., Fanning S., O'Mahony R., and Kyne L. Isolation and characterisation of toxin A-negative, toxin B-positive Clostridium difficile in Dublin, Ireland. Clin Microbiol Infect 13 (2007) 298-304
7. Kim H., Riley T.V., Kim M., Kim C.K., Yong D., Lee K., et al. Increasing prevalence of toxin A-negative, toxin B-positive isolates of Clostridium difficile in Korea: impact on laboratory diagnosis. J Clin Microbiol 46 (2008) 1116-1117
8. Johnson S., Samore M.H., Farrow K.A., Killgore G.E., Tenover F.C., Lyras D., et al. Epidemics of diarrhea caused by a clindamycin-resistant strain of Clostridium difficile in four hospitals. N Engl J Med 341 (1999) 1645-1651
9. Nelson D.E., Auerbach S.B., Baltch A.L., Desjardin E., Beck-Sague C., Rheal C., et al. Epidemic Clostridium difficile-associated diarrhea: role of second- and third-generation cephalosporins. Infect Control Hosp Epidemiol 15 (1994) 88-94
10. Ackermann G., Tang Y.J., Kueper R., Heisig P., Rodloff A.C., Silva Jr. J., et al. Resistance to moxifloxacin in toxigenic Clostridium difficile isolates is associated with mutations in gyrA. Antimicrob Agents Chemother 45 (2001) 2348-2353
11. Dridi L., Tankovic J., Burghoffer B., Barbut F., and Petit J.C. gyrA and gyrB mutations are implicated in cross-resistance to ciprofloxacin and moxifloxacin in Clostridium difficile. Antimicrob Agents Chemother 46 (2002) 3418-3421
12. Spigaglia P., Barbanti F., Mastrantonio P., Brazier J.S., Barbut F., Delmée M., et al. Fluoroquinolone resistance in Clostridium difficile isolates from a prospective study of C. difficile infections in Europe. J Med Microbiol 57 (2008) 784-789
13. Chang S.Y., and Song K.P. ADP-ribosylating binary toxin genes of Clostridium difficile strain CCUG 20309. DNA Seq 12 (2001) 115-120
14. Hammond G.A., and Johnson J.L. The toxigenic element of Clostridium difficile strain VPI 10463. Microb Pathog 19 (1995) 203-213
15. Mehlig M., Moos M., Braun V., Kalt B., Mahony D.E., and von Eichel-Streiber C. Variant Toxin B and a Functional Toxin A Produced by Clostridium difficile C34. FEMS Microbiol Lett 198 (2001) 171-176
16. Cohen S.H., Tang Y.J., and Silva Jr. J. Analysis of the pathogenicity locus in Clostridium difficile strains. J Infect Dis 181 (2000) 659-663
17. Haslam S.C., Ketley J.M., Mitchell T.J., Stephen J., Burdon D.W., and Candy D.C. Growth of Clostridium difficile and production of toxins A and B in complex and defined media. J Med Microbiol 21 (1986) 293-297
18. Sebaihia M., Wren B.W., Mullany P., Fairweather N.F., Minton N., Stabler R., et al. The multidrug-resistant human pathogen Clostridium difficile has a highly mobile, mosaic genome. Nat Genet 38 (2006) 779-786
19. Popoff M.R., Rubin E.J., Gill D.M., and Boquet P. Actin-specific ADP-ribosyltransferase produced by a Clostridium difficile strain. Infect Immun 56 (1988) 2299-2306
20. Perelle S., Gibert M., Bourlioux P., Corthier G., and Popoff M.R. Production of a complete binary toxin (actin-specific ADP-ribosyltransferase) by Clostridium difficile CD196. Infect Immun 65 (1997) 1402-1407
21. Chaves-Olarte E., Low P., Freer E., Norlin T., Weidmann M., von Eichel-Streiber C., et al. A novel cytotoxin from Clostridium difficile serogroup F is a functional hybrid between two other large clostridial cytotoxins. J Biol Chem 274 (1999) 11046-11052
22. Moncrief J.S., Zheng L., Neville L.M., and Lyerly D.M. Genetic Characterization of Toxin A-Negative, Toxin B-Positive Clostridium difficile Isolates by PCR. J Clin Microbiol 38 (2000) 3072-3075
23. Torres J.F. Purification and characterization of toxin B from a strain of Clostridium difficile that does not produce toxin A. J Med Microbiol 35 (1991) 40-44
24. Rafii F., Park M., and Novak J.S. Alterations in DNA gyrase and topoisomerase IV in resistant mutants of Clostridium perfringens found after in vitro treatment with fluoroquinolones. Antimicrob Agents Chemother 49 (2005) 488-492
25. Balassiano I.T., Miranda K.R., Boente R.F., Pauer H., Oliveira I.C., Santos-Filho J., et al. Characterization of Clostridium difficile strains isolated from immunosuppressed inpatients in a hospital in Rio de Janeiro, Brazil. Anaerobe Jan 13 (2009) Epub ahead of print
26. Warny M., Pepin J., Fang A., Killgore G., Thompson A., Brazier J., et al. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet 366 9491 (2005) 1079-1084
27. Drudy D., Kyne L., O'Mahony R., and Fanning S. gyrA mutations in fluoroquinolone-resistant Clostridium difficile PCR-027. Emerg Infect Dis 13 (2007) 504-505
28. Stubbs S., Rupnik M., Gibert M., Brazier J., Duerden B., and Popoff M. Production of actin-specific ADP-ribosyltransferase (binary toxin) by strains of Clostridium difficile. FEMS Microbiol Lett 186 (2000) 307-312